Abstract 1821P
Background
Cardiovascular disease (CVD) is a leading cause of death in men with prostate cancer (PC). Androgen deprivation therapy (ADT) may increase this risk. GnRH agonists or antagonists induce equivalent castration but have a distinctive effect on follicle-stimulating hormone (FSH). We hypothesize that FSH mediates the atherogenic and cardiovascular effects associated with testosterone (T) deficiency.
Methods
We investigated mouse models of atherosclerosis using gain and loss of FSH and two clinical studies with primary CVD endpoints. Low-density lipoprotein receptor-deficient (LDLR-/-) and FSHβ-/-;LDLR-/- mice were treated with different modes of ADT for 14 weeks and aortic atherosclerotic plaque, its necrotic and inflammatory content and serum hormones were determined. In a prospective cohort of PC patients commencing on ADT, serum FSH and T were determined after three and six months and related to the development of cardiovascular events. In a prospective nested case-control study of 848 men undergoing surgery, serum FSH and T were related to the development of cardiovascular event.
Results
Compared to LDLR-/- mice, FSHβ-/-;LDLR-/- mice, untreated or castrated, demonstrated significantly less atherosclerosis, but not following delivery of FSH. The significant differences in necrotic core and total atherosclerotic plaque in mice treated with GnRH-agonists vs. antagonists were nullified by loss of FSH in the FSHβ-/-;LDLR-/- mice. Atherosclerotic plaque, its necrotic and inflammatory content, correlated significantly with the serum FSH/T ratio. In PC patients commencing on ADT, serum FSH/T after three and six months significantly predicted the development of cardiovascular event. In men undergoing surgery, high FSH/T ratio increased odds of a postoperative cardiovascular event by 39% (95% CI 3-87%).
Conclusions
FSH facilitates CVD in men with low or castrated T. Serum FSH/T ratio associates with the risk of developing a cardiovascular event following a stressful cardiovascular trigger such as ADT or surgery. Accordingly, GnRH-antagonists associated with lower necrotic and atherosclerotic plaque burden in mice and clinically, with significantly lower serum FSH/T levels and fewer cardiovascular events compared to GnRH-agonists.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
J. H. Pinthus.
Funding
Ferring.
Disclosure
J.H. Pinthus, D. Margel: Financial Interests, Personal, Research Grant: Ferring. All other authors have declared no conflicts of interest.
Resources from the same session
1940P - Deep molecular profiling of advanced synovial sarcoma as a basis for interventional clinical trials
Presenter: Richard Schlenk
Session: Poster session 15
1941P - Preliminary efficacy and safety of SHR-2554 in advanced epithelioid sarcoma: A phase II trial
Presenter: Haiyan Hu
Session: Poster session 15
1942P - Non-metastatic malignant phyllodes tumors of the breast (B-MPT): A retrospective analysis from a referral center
Presenter: Carmine Valenza
Session: Poster session 15
1944P - MAGE-A4 and NY-ESO-1 expression analysed in a synovial sarcoma tissue micro-array
Presenter: Lore De Cock
Session: Poster session 15
1945P - Diagnostic and therapeutic impact of liquid biopsy in soft tissue sarcomas: A case series
Presenter: Tarek Assi
Session: Poster session 15
1946P - Bladder primary sarcomas (BSar): A genomic landscape and clinical outcomes study
Presenter: ALINA BASNET
Session: Poster session 15
1947P - Predictors and outcomes of recurrent retroperitoneal liposarcoma: New insights into its recurrence patterns
Presenter: Huan Deng
Session: Poster session 15
1948P - Concordance of the pathological diagnosis between local institutional and central judgment in high-grade non-round-cell sarcomas: A supplementary analysis of JCOG1306
Presenter: Eisuke Kobayashi
Session: Poster session 15
1949P - Pegylated liposomal doxorubicin (PLD) combined with trabectedin as a treatment option in uterine sarcomas
Presenter: Laura Strobel
Session: Poster session 15